The FDA granted breakthrough therapy designation to an experimental drug from Amgen for patients with FGFR2b over expressing and HER2-negative gastric cancer.
Enhertu from Daiichi-Sankyo is now approved in Japan for the treatment of HER2-positive gastric cancer.
Combining Cyramza with IMFINZI® (durvalumab) was safe and effective in a small trial that included gastric cancer patients.
Pieris and Eli Lilly have partnered to test a combination of Cyramza, paclitaxel and Pieris’ novel bispecific antibody in HER2-positive gastric cancer.
MacroGenics received orphan drug designation from the FDA for its investigational gastric cancer drug margetuximab.
A recent trial of a combination of Stivarga and Opdivo showed better activity than either drug alone in patients with gastric cancer.
The FDA approved Deciphera Pharmaceuticals’ Quinlock (ripretinib) for the treatment of advanced gastrointestinal stromal tumors.